No Data
Catalent Gains After Report Sale to Novo Holdings Could Close Soon
Evotec And Novo Nordisk Launch First Projects For LAB EN2 Accelerator, Focusing On Cardiometabolic Diseases
BofA Restarts Coverage of 11 Large-cap Biopharmas
Jim Cramer Is 'Not A Fan' Of Novavax, Says This Tech Stock Is 'Expensive'
How Much Did Americans Overspend On Weight Loss Medications in 2024? GoodRx Reveals
The "weight loss duo" faced off for the first time: eli lilly and co won against novo-nordisk a/s, goldman sachs: the market has already known.
Goldman Sachs stated that this result is in line with the general market expectations, which indicate that Zepbound's weight loss effects are significantly better than Novo Nordisk. It is believed that Novo Nordisk and Eli Lilly and Co will control 80% of the weight loss medication market, with a ratio of 40% and 60% between the two.
